| Literature DB >> 32373267 |
Luis Caraballo1, Rudolf Valenta2,3,4, Leonardo Puerta1, Anna Pomés5, Josefina Zakzuk1, Enrique Fernandez-Caldas6, Nathalie Acevedo1, Mario Sanchez-Borges7, Ignacio Ansotegui8, Luo Zhang9, Marianne van Hage10, Eva Fernández5, Luisa Arruda11, Susanne Vrtala2, Mirela Curin2, Hans Gronlund12, Antonina Karsonova4, Jonathan Kilimajer6, Ksenja Riabova4, Daria Trifonova4, Alexander Karaulov4.
Abstract
A large number of allergens have been discovered but we know little about their potential to induce inflammation (allergenic activity) and symptoms. Nowadays, the clinical importance of allergens is determined by the frequency and intensity of their IgE antibody binding (allergenicity). This is a rather limited parameter considering the development of experimental allergology in the last 20 years and the criteria that support personalized medicine. Now it is known that some allergens, in addition to their IgE antibody binding properties, can induce inflammation through non IgE mediated pathways, which can increase their allergenic activity. There are several ways to evaluate the allergenic activity, among them the provocation tests, the demonstration of non-IgE mediated pathways of inflammation, case control studies of IgE-binding frequencies, and animal models of respiratory allergy. In this review we have explored the current status of basic and clinical research on allergenic activity of indoor allergens and confirm that, for most of them, this important property has not been investigated. However, during recent years important advances have been made in the field, and we conclude that for at least the following, allergenic activity has been demonstrated: Der p 1, Der p 2, Der p 5 and Blo t 5 from HDMs; Per a 10 from P. americana; Asp f 1, Asp f 2, Asp f 3, Asp f 4 and Asp f 6 from A. fumigatus; Mala s 8 and Mala s 13 from M. sympodialis; Alt a 1 from A. alternata; Pen c 13 from P. chrysogenum; Fel d 1 from cats; Can f 1, Can f 2, Can f 3, Can f 4 and Can f 5 from dogs; Mus m 1 from mice and Bos d 2 from cows. Defining the allergenic activity of other indoor IgE antibody binding molecules is necessary for a precision-medicine-oriented management of allergic diseases.Entities:
Year: 2020 PMID: 32373267 PMCID: PMC7195550 DOI: 10.1016/j.waojou.2020.100118
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 4.084
Assays to evaluate allergenic activity and clinical relevance of allergens
| Assay | Comment |
|---|---|
| IgE-binding capacity | Evaluates allergenicity, an important component of allergenic activity. |
| The most representative test of clinical relevance. | |
| Evaluate IgE-dependent cellular activation. | |
| Case control studies | Statistical support of clinical relevance |
| Mechanisms of action | Evaluate additional, non-IgE mediated, inflammatory pathways. |
| Animal model of allergy | Supports the hypothesis of clinical relevance |
| Passive cutaneous anaphylaxis | Induction of a specific IgE response |
| Avoidance studies | An indirect way to confirm clinical effects |
| Component specific immunotherapy | Supports causality and confirms clinical relevance |
Allergenic activity assays accomplished by house dust mite allergens (In addition to IgE-binding)
| Provocation test | Provocation test | Non-IgE induced inflammation | Case-control study | Respiratory | PCA animal model | Avoidance | AIT trials | |
|---|---|---|---|---|---|---|---|---|
| Der p 1 | ST, B | BAT, HR | Yes | Asthma | Asthma | Yes | Yes | Yes |
| Der p 2 | ST, B | BAT, HR | Yes | Asthma | Asthma | Yes | Yes | |
| Der p 5 | ST | HR | Yes | Asthma | Asthma | |||
| Der p 3 | BAT, RBL | Yes | Asthma | |||||
| Der p 10 | ST | Asthma | Yes | |||||
| Der p 21 | ST | BAT | Asthma | |||||
| Der p 13 | BAT, HR | Yes | ||||||
| Der p 23 | BAT | Asthma | ||||||
| Der p 18 | BAT | |||||||
| Der p 24 | HR | |||||||
| Blo t 5 | ST | BAT, HR | Yes | Asthma | Asthma | Yes | ||
| Blo t 8 | ST | Asthma | Yes | |||||
| Blo t 10 | ST | Asthma | ||||||
| Blo t 12 | ST | Asthma | ||||||
| Blo t 13 | ST | HR | ||||||
| Blo t 2 | RBL, HR | |||||||
| Blo t 7 | Yes | |||||||
| Blo t 11 | ST |
PCA: Passive cutaneous anaphilaxis; AIT: Allergen Immunotherapy; ST: Skin test; BAT: Basophil Activation test; HR: Histamine release; RBL: Rat Basophil Leukemia cells test
Fig. 1The immunoblotting shows the IgE antibody binding profile obtained using sera form 8 Spanish patients with allergy to A. alternata. All patients show IgE antibody binding to the Alt a 1 allergen with high intensity
Allergenic activity assays accomplished by some purified fungal allergens (In addition to IgE-binding)
| Allergen | Provocation test | Provocation test | Non-IgE induced inflammation | Case-control study | Respiratory | PCA animal model | Avoidance | AIT trials |
|---|---|---|---|---|---|---|---|---|
| Asp f 2 | ST | HR | Yes | ABPA, CF + ABPA | Yes | Mouse model IT | ||
| Alt a 1 | ST | HR | Yes | Yes | Human IT | |||
| Pen c 13 | ST | HR | Yes | Asthma/Rhintis | Yes | |||
| Asp f 4 | ST | HR | Yes | ABPA, asthma + bronchiectasis, | Yes | |||
| Asp f 6 | ST | HR | Yes | ABPA, | Yes | |||
| Asp f 1 | ST | BAT | Yes | Asthma | Yes | |||
| Asp f 3 | ST | Yes | Asthma, asthma + bronchiectasis | Yes | ||||
| Mala s 8 | ST | HR | Atopic eczema | |||||
| Mala s 13 | ST | Yes | Atopic eczema | |||||
| Asp f 13 | Yes | Yes | ||||||
| Asp f 5 | Yes | Yes | ||||||
| Alt a 8 | ST | |||||||
| Cla h 8 | ST |
PCA: Passive cutaneous anaphilaxis; AIT: Allergen Immunotherapy; ABPA: Allergic Bronchopulmonary aspergillosis; CF: Cystic fibrosis; ST: Skin test; BAT: Basophil Activation test; HR: Histamine release
Allergenic activity assays accomplished by some purified pets allergens (In addition to IgE-binding).
| Allergen | Provocation test | Provocation test | Non-IgE induced inflammation | Case-control study | Respiratory | PCA animal model | Avoidance | AIT trials |
|---|---|---|---|---|---|---|---|---|
| Fel d 1 | ST | BAT, RBL | Yes | Asthma, Rhinitis, | Yes | Yes | ||
| Can f 1 | ST | BAT | Asthma, Rhinitis, | Yes | ||||
| Can f 2 | ST | BAT | Asthma, Rhinitis | |||||
| Can f 3 | ST, NPT | BAT | Rhinitis, Asthma, Skin symptoms | |||||
| Can f 4 | ST, NPT | BAT | ||||||
| Can f 5 | ST, NPT | BAT | Rhinitis, Asthma, | |||||
| Can f 6 | ST | BAT | ||||||
| Mus m 1 | NPT, ST | BAT | Yes | Asthma | ||||
| Bos d 2 | NPT, ST | Yes | Asthma | |||||
| Equ c 1 | BAT | Asthma, Rhinitis | ||||||
| Ory c 3 | BAT | Asthma, Rhinitis, | ||||||
| Rat n 1 | BAT | Asthma | ||||||
| Cav p 2 | BAT, RBL | |||||||
| Cav p 3 | BAT, RBL |
PCA: Passive cutaneous anaphylaxis; AIT: Allergen Immunotherapy; ST: Skin test; NPT: Nasal provocation test; BAT: Basophil Activation test; RBL: Rat Basophil Leukemia test